Clinical Trial Update: A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ATG-010 in relapsed/refractory multiple myeloma has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ATG-010

Snippet

Sponsor: Antengene Corporation | Conditions: Relapse/Refractory Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2023-06-15